A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

BACKGROUND: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover’s disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. CASE PRESENTATION: We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, Marc, Faisal, Faa’k, Haymaker, Cara, McQuail, Natalie, Sirmans, Elizabeth, Hudgens, Courtney W., Barbara, Lydia, Bernatchez, Chantale, Curry, Jonathan L., Hwu, Patrick, Tetzlaff, Michael T., Diab, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028978/
https://www.ncbi.nlm.nih.gov/pubmed/27660709
http://dx.doi.org/10.1186/s40425-016-0157-6
_version_ 1782454437385601024
author Uemura, Marc
Faisal, Faa’k
Haymaker, Cara
McQuail, Natalie
Sirmans, Elizabeth
Hudgens, Courtney W.
Barbara, Lydia
Bernatchez, Chantale
Curry, Jonathan L.
Hwu, Patrick
Tetzlaff, Michael T.
Diab, Adi
author_facet Uemura, Marc
Faisal, Faa’k
Haymaker, Cara
McQuail, Natalie
Sirmans, Elizabeth
Hudgens, Courtney W.
Barbara, Lydia
Bernatchez, Chantale
Curry, Jonathan L.
Hwu, Patrick
Tetzlaff, Michael T.
Diab, Adi
author_sort Uemura, Marc
collection PubMed
description BACKGROUND: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover’s disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. CASE PRESENTATION: We report an additional case of ipilimumab-induced Grover’s disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. CONCLUSION: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.
format Online
Article
Text
id pubmed-5028978
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50289782016-09-22 A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1 Uemura, Marc Faisal, Faa’k Haymaker, Cara McQuail, Natalie Sirmans, Elizabeth Hudgens, Courtney W. Barbara, Lydia Bernatchez, Chantale Curry, Jonathan L. Hwu, Patrick Tetzlaff, Michael T. Diab, Adi J Immunother Cancer Case Report BACKGROUND: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover’s disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. CASE PRESENTATION: We report an additional case of ipilimumab-induced Grover’s disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. CONCLUSION: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study. BioMed Central 2016-09-20 /pmc/articles/PMC5028978/ /pubmed/27660709 http://dx.doi.org/10.1186/s40425-016-0157-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Uemura, Marc
Faisal, Faa’k
Haymaker, Cara
McQuail, Natalie
Sirmans, Elizabeth
Hudgens, Courtney W.
Barbara, Lydia
Bernatchez, Chantale
Curry, Jonathan L.
Hwu, Patrick
Tetzlaff, Michael T.
Diab, Adi
A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
title A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
title_full A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
title_fullStr A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
title_full_unstemmed A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
title_short A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
title_sort case report of grover’s disease from immunotherapy-a skin toxicity induced by inhibition of ctla-4 but not pd-1
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028978/
https://www.ncbi.nlm.nih.gov/pubmed/27660709
http://dx.doi.org/10.1186/s40425-016-0157-6
work_keys_str_mv AT uemuramarc acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT faisalfaak acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT haymakercara acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT mcquailnatalie acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT sirmanselizabeth acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT hudgenscourtneyw acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT barbaralydia acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT bernatchezchantale acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT curryjonathanl acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT hwupatrick acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT tetzlaffmichaelt acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT diabadi acasereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT uemuramarc casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT faisalfaak casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT haymakercara casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT mcquailnatalie casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT sirmanselizabeth casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT hudgenscourtneyw casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT barbaralydia casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT bernatchezchantale casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT curryjonathanl casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT hwupatrick casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT tetzlaffmichaelt casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1
AT diabadi casereportofgroversdiseasefromimmunotherapyaskintoxicityinducedbyinhibitionofctla4butnotpd1

Ejemplares similares